Enanta Pharmaceuticals Added to the Russell 3000® and Russell 2000® Indexes
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that it has been added to the Russell 3000®Index and the Russell 2000® Index as part of the annual reconstitution of the Russell indexes. The reconstitution was final after the close of the U.S. markets on June 28, 2013.
The Russell 3000 Index is designed to measure the performance of the largest 3000 U.S. companies, which represent approximately 98% of the investable U.S. equity market. The Russell 2000 Index, a subset of the Russell 3000® Index, is designed to measure the performance of the small-cap segment, which represents approximately 10% of the total market capitalization of the Russell 3000. The Russell 3000 Index and its subset indexes are reconstituted annually to ensure new equities are reflected.
Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. Enanta is discovering and developing novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes protease (partnered with AbbVie), NS5A (partnered with Novartis) and nucleotide polymerase as well as a host-targeted antiviral (HTA) inhibitor class targeted against cyclophilin. Additionally, Enanta has created a new class of antibiotics, called Bicyclolides, for the treatment of multi-drug resistant bacteria, with a current focus on developing an intravenous and oral treatment for hospital and community MRSA (methicillin-resistant Staphylococcus aureus) infections.
Enanta Pharmaceuticals, Inc.
Carol Miceli, 617-607-0710
Source: Enanta Pharmaceuticals, Inc.Copyright Business Wire 2013